leadf
logo-loader
viewAstraZeneca

AstraZeneca's Brilinta get approval for use in stroke alongside aspirin

The US Food & Drug Administration green light followed a successful phase III study of the drug, also known as ticagrelor, in combination with aspirin

AstraZeneca -

AstraZeneca PLC's (LON:AZN) Brilinta has been approved in the US for patients that have suffered acute ischemic and high-risk transient ischaemic strokes.

The US Food & Drug Administration green light followed a successful phase III study of the drug, also known as ticagrelor, in combination with aspirin.

In a statement, the lead investigator of the study, Dr Clay Johnston, said: "One in four patients who have had a stroke will experience a second one, with the risk particularly high within the first 30 days.

“The approval of Brilinta in combination with aspirin is an important advancement to reduce the risk of recurrent stroke and much-awaited good news for physicians and patients."

Quick facts: AstraZeneca

Price: 7674 GBX

LSE:AZN
Market: LSE
Market Cap: £100.73 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

SourceBio International reveal revenues rose to over £50m for 2020 and set...

SourceBio International PLC's (LON:SBI) Jay LeCoque talks to Proactive London's Katie Pilbeam about their 2020 results.  LeCoque explains what drove revenues for the 12 months ended December 31, 2020, up to £50.7mln, from £21.2mln in 2019. Another headline figure was the underlying...

1 hour, 11 minutes ago

2 min read